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Summary Impetigo herpetiformis (IH) is a rare pustular typically
occurring during pregnancy. Based upon a similar clinical and histological presentation, i.e. 
spongiform accumulation of polymorphonuclear leucocytes in the stratum corneum, several authors
consider IH as a variant of generalized pustular psoriasis (GPP), while others state that IH is a 
separate entity. Skin-derived antileucoproteinase (SKALP) is a strong and specific inhibitor of human 
leucocyte elastase (FILE) and proteinase 3, two neutral proteinases that have been implicated in 
leucocyte migration and tissue destruction. Previously, we reported decreased SKALP activity in 
pustular forms of psoriasis compared with plaque psoriasis. In this study we present a case study of a 
patient with IFI, where SKALP activity was measured using biochemical and immunochemical 
techniques. Epidermal scales and sera were collected during the course of the disease. Comparison 
was made with three patients with GPP and six patients with plaque psoriasis. Initially, anti-HLE 
activity in epidermal scales of the patient with IH was comparable with values in patients with GPP, 
i.e. decreased compared with plaque psoriasis. During the course of the disease, anti-elastase activity
dropped to undetectable levels, concomitant with the appearance of free elastase activity. This ii
suggests a total saturation of epidermal anti-HLE activity. Low levels of SKALP, presumably 
complexed with HLE, could be measured immunochemically in scale extracts. Serum levels of 
total SKALP correlated with the disease activity. We suggest that a reduced amount of epidermal 
SKALP contributes to an imbalance between elastase and its inhibitor, resulting in the formation of 
epidermal pustules. This mechanism of pustule formation could apply both to GPP ; 
suggesting a final common pathway in the pathogenic mechanisms of IH and GPP.
Impetigo herpetiformis (IH) is a rare pustular dermatosis 
with unknown aetiology, that typically affects pregnant 
women. Both the clinical and the histological presenta­
tion resemble the generalized form of pustular psoriasis. 
Apart from erythema and scaling, the main character­
istic of both these conditions is the presence of macro­
scopic pustules, which are the result of an extreme 
epidermal infiltration of polymorphonuclear leucocytes 
(PMN). The pathogenic events leading to the formation 
of macropustules in these diseases are unknown. Both 
an increase of epidermal chemotactic factors1'2 and an 
increased chemotactic response of the PMN} have been 
implicated as a factor contributing to the massive PMN 
inllux.
Activated PMN secrete a variety of destructive pro­
ducts, lor example proteinases (e.g. human leucocyte
elastase (FILE) and proteinase 3). One of 
functions of HLE is to facilitate 
connective tissue and basal membranes towards inllam-
matory T activity of proteinases is regulated
systemically by numerous plasma-derived inhibitors, 
such as a  i-proteinase a..-macrog
We and others have characterized an inducible epider­
mal proteinase inhibitor, which is absent in normal skin 
and upregulated in inflammatory skin diseases such as 
psoriasis. This inhibitor has been named skin-derived 
antileucoproteinase (SKALP)/’ also known as elalin/ or
elastase-speeilic inhibitor (ESI).8 J5 has
shown to be a potent inhibitor of HLE and proteinase 
3.4 We also showed that SKALP expression by epidermal 
keratinocytes protects against elastase-mediated loss of 
cell adhesion.10 We found that the levels of SKALP in
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scale extracts from patients with a pustular form, of 
psoriasis were far lower than in chronic plaque psor­
iasis. Furthermore, free elastase activity was found in 
the scale extracts of 25% of the pustular psoriasis
patients, a total saturation of epidermal
SKALP activity. Based on these findings, we proposed 
a new mechanism for pustule formation: consumption 
of SKALP, which is extreme in pustular psoriasis, can 
lead to local SKALP deficiencies which allow a facili­
tated migration of PMN, resulting in the formation of 
pustules.
A similar mechanism for pustule formation could 
apply to IH. Here we present a case report of a patient
with IH, in which we studied the SKALP activity in scale 
extracts and serum levels during the course of the 
disease.
Figure 1. A typical lesion in a patient with impetigo herpetiformis. 
Pustules are predominantly present in the periphery encircling a 
central area with desquamation.
however, serum 25 hydroxyvitamin D 3 was slightly
Case report
A 31-year-old pregnant woman was admitted with a 
sudden onset of erythema, scaling and pustule forma-
decreased. Bacterial cultures of the pustule content 
were sterile. HLA-B27 typing was negative.
Histopathological investigation of a macroscopic pus­
tule showed an acanthotic epidermis with slight hyper-
tion at 31 weeks gestation. The lesions started on the keratosis, PMN accumulated in the subcorneal layer
¥
dorsum of the hands and spread rapidly. She complained 
of burning sensations in her skin and general malaise. 
This was her third pregnancy. The first one ended in a
and in the upper part of the stratum spinosum, accom­
panied by spongiosis. The dermis showed a slight peri­
vascular inflammatory infiltrate composed of
spontaneous abortion at 11 weeks gestation, with the 
second pregnancy resulting in delivery of a healthy full- 
term child. During these previous pregnancies she did 
not suffer from any skin problems. The patient had no 
history of psoriasis or other skin diseases, nor did
lymphocytes and PMN, the latter tending to migrate 
to the upper part of the dermis (Fig. 2).
In view of the clinical and histological findings, IH 
was diagnosed. Treatment was started with moderate 
potency local corticosteroids. The albumin level was
psoriasis occur in her family. She was not receiving 
any medication except for ferrous fumarate because of 
low haemoglobin.
On the trunk she had polycyclic, confluent, sharply 
demarcated, bright red lesions with scales and pustule 
formation (Fig. 1). The face, inguinal folds, anal region 
and knee folds were also involved. The pustules did not 
coalesce: they occurred predominantly at the periphery 
of the lesions, encircling a central area with desquama­
tion. The oral cavity was also involved, showing pus­
tules on the mucosa and tongue. The nails showed no 
abnormalities. She did not have a fever.
Laboratory investigations showed decreased haemo­
globin (6*3mmol/L), an increased white blood cell 
count (20'9 x 10y/L), increased sedimentation rate
normalized by an intravenous infusion of 20% albumin 
solution. Subsequently, the patient was transferred to 
the department of obstetrics for intensive foetal mon­
itoring. After 5 days without clinical improvement, 
therapy was started with prednisone, initially 30 mg 
daily and later increased to 50 mg daily, and calcitriol, 
in a dosage of 0*5 fig daily: however, without clinical 
response. At 3 7 weeks gestation, labour started sponta­
neously and she delivered a healthy child. Improvement 
in the skin lesions after delivery was slow: after 2 weeks 
isotretinoin was started in a dosage of 20 mg daily, and 
prednisone was gradually reduced over a 3-month 
period. The pustules and erythema disappeared within 
2 weeks from starting isotretinoin. Local emollients 
were started. After 4 months no skin lesions remained
(52 mm in the first hour), normal creatinine, electro- and isotretinoin was discontinued. She has remained
lytes, glucose and liver enzymes. The phosphate level 
was low normal, and the calcium level (2-01 mmol/L)
disease free for 2 Vi years.
was just in the normal range after compensation for a 
low albumin level (27 g/L). Serum levels of parathyroid 
hormone and 1,25 dihydroxyvitamin D 5 were normal;
Materials and methods
Clinical scores for pustulation were made at regular
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Figure 2. Acanthotic epidermis with 
hyperkeratosis. Polymorphonuclear 
leucocytes (FMN) are infiltrating in the 
stratum spinosum and stratum corneum 
and form an intracomeal pustule. In the 
dermis a slight mixed perivascular infiltrate 
composed of lymphocytes and PMN is 
present (haematoxylin and eosin staining, 
bar represents 100 am).
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intervals: 0, no pustulation; 1, slight pustulation; 2, 
moderate pustulation; 3, severe pustulation. Epidermal 
scales and sera were collected from our patient during 
the course of the disease. Epidermal scales could only be 
collected in the initial phase, because later there was 
insufficient scaling. In addition, epidermal scales were 
collected from three patients with GPP and six patients 
with plaque psoriasis. Scales and sera were stored at 
20°C for later analysis.
Scales were processed for determination of SKALP 
activity.11 They were weighed, homogenized (100 mg/ 
mL) in a glass-glass grinder in phosphate-buffered saline 
(PBS) and centrifuged (15min, 12,000#). The clear' 
supernatant was divided into two equal portions. One 
portion was boiled for 2 min to inactivate elastase and to 
liberate the elastase-bound inhibitor and then centri-
mm
performed
the Bio-Rad DC Protein Assay (Bio-Rad Laboratories, 
Richmond, CA, U.S.A.).
elastase activity in scales
In epidermal scales a direct quantification of the total 
amount of biologically active SKALP is not possible, 
because both free elastase and elastase complexed with 
inhibitor can be found. Our method, used for the 
measurement of anti-elastase activity in urine, 
based on the differential heat-stability of elastase and 
SKALP. Elastase is denatured by boiling the scale 
extracts for 2 min, whereas SKALP is heat-stable, and
12 IS
latent SKALP is released from the enzyme-inhibitor 
complex. In all scale extracts we measured the free 
SKALP activity in untreated samples and the total, 
latent plus free, SKALP activity in heat-inactivated 
samples. Another complicating factor is the possible 
presence in human skin of at least two other high- 
affinity elastase inhibitors beside SKALP, either free or 
complexed. These are alpha-1-antitrypsin (alpha-1-AT) 
and secretory leucocyte protease inhibitor (SU ’D, which 
is identical to antileucoproteinase (ALP).1 } From pre­
vious studies we know that SLPI activity is present 
in scales,9 but in relatively low concentration com­
pared with that of SKALP (unpublished data). Disturb­
ance by alpha-1-AT activity is eliminated in the assay
by the presence of 
(CTAB).14 Therefore, almost all of the anti-elastase 
activity measured in our assay represents SKALP activity 
Elastase activity was measured as the release of I he 
tluorogenic substrate methoxy-sueeinyl-alanyl-ahmyl- 
prolyl-valyl-amino-4-methyleoumarin (M A AP V-A M t\  
Sigma, St Louis, MO, U.S.A.).1 s Anti-HLE activity was 
measured as the percentage inhibition of a standard
i me same assay, i* 
was measured at 3 75 nm (excitation) and 4 4 0  nm 
(emission) in a Shimadzu RF-5001 PC spcclroiluoro- 
photometer (Shimadzu Corp., Kyoto, Japan),
Serial dilutions were made from the samples in 
assay buffer (Im ol/L NaCl, 0-4% CTAB, 0-1 moI/L Tris 
pH 8-5). Ten juL containing an extract of 500 PMN in
1 ng HLE) was mixed with 
10 ixL of serial dilutions of scale extract and then 
incubated for 15 min at 37°C. Thereafter, 20 ¡xL of
******
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y 50 /xtnol/L elastase substrate solution was added and 
the reaction was allowed to proceed for 15 min at 37°C. 
rrhe incubation was terminated by the addition of 1 niL 
stop buffer (lOOmmol/L Na2C0 pH 10*5). Inhibition
of elastase activity in this assay was calculated as the 
percentage inhibition of the activity of 500 PMN, within 
the linear range of the assay. Recombinant SKALP/elafin 
(a kind gift of Dr N.Russell, Zeneca, U.K.) was used to 
obtain a calibration curve from which the anti-HLE con­
centration in the scale extracts was read. Alter correction 
for protein concentration, anti-HLE activity was expressed 
in nanograms of SKALP per milligram of protein.
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Enzyme-linked immunosorbent assay (ELISA) for 
measurement of SKALP levels
SKALP concentrations were measured in scale extracts 
and sera, using a sandwich-type ELISA. Scale extracts 
were boiled and supernatants were taken for quantifica­
tion of SKALP, sera were measured directly. Samples 
were mixed to contain 10% sample, 0-lm ol/L Tris, 
0-1% Tween-20, 1% bovine serum albumin (BSA). 
Microtitre plates (96 flat bottom wells) were coated 
overnight with goat anti-SIC ALP antiserum. After wash­
ing the plate with PBS with 0-05% Tween-20, micro- 
titre plates were blocked and probed with the test 
samples. Subsequently, rabbit anti-SICALP antiserum 
with 2-5% normal goat serum was added and developed 
for 60 min with peroxidase-conjugated swine-antirabbit 
immunoglobulin with 2*5% normal goat serum using 
o-phenylenediamine dihydrochloride (OPD) as chromo- 
genic substrate for 15 min. Human recombinant SICALP/ 
elafin in PBS with 0-1% BSA was used as a standard; a 
calibration curve was made, using recombinant SICALP/ 
elafin in the range of 0*5-120 ng/mL. The SICALP 
concentrations in scales or serum samples were read 
from this curve. All ELISA steps were performed at room 
temperature. Data were read with a BioradIM ELISA- 
reader, and evaluated using the ExcelIM spread sheet 
program. After correction for protein concentration, 
SKALP activity was expressed in nanograms of SKALP 
per milligram of protein. The ELISA used in this study 
was specific for SKALP and does not recognize SLFI (not 
shown).
Results
Anti-human leucocyte elastase activity in scale extracts
Using a functional assay we measured the free anti-HLE 
activity in untreated samples and the total, latent plus 
free, anti-HLE activity in heat-inactivated samples. In
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Figure 3. (a) Anti-human leucocyte elastase (HLE) activity in serial 
scale extracts of a patient with impetigo herpetiformis (IH). Day 0 is 
the day of admission, Anti-HLE activity was measured with a func­
tional assay directly (triangles) and after heat inactivation (dots). 
Initially the untreated samples show skin-derived antileucoproteinase 
(SKALP) activity; however, after 9 days free elastase activity was 
present in all the following samples, In all those samples, SKALP 
activity could be recovered after heat inactivation, (b) Anti-HLE 
activity and SKALP levels in scale extracts of patients with IH 
(n =  .1), generalized pustular psoriasis (GPP) (n =  3), chronic plaque 
psoriasis ( ji=  6). The mean value of 11 samples collected over 20 days 
was used for the values of the patient with IH (see part (a)). Anti-HLE 
activity was determined with a functional assay directly (tilled bars) 
and after heat inactivation (open bars). Heat inactivation releases the 
SKALP that was complexed with HLE, Note the increase in anti-HLE 
activity following heat inactivation of scale extracts from the GPP 
patients and the IH patient. The hatched bars represent SKALP levels 
as measured with ELISA. SKALP levels were substantially lower in the 
patient with IH and in the GPP group compared with the plaque 
psoriasis group. This was found both with functional measurements, 
which measure anti-HLE activity, and with ELISA techniques, which 
measure immunoreactive SKALP.
the untreated samples of our patient with IH, anti-HLE 
activity could be measured during the first 7 days after 
admission. In all subsequent samples, anti-HLE activity 
was undetectable, but free elastase activity could be 
measured. Anti-HLE activity could be detected after heat 
inactivation (Fig. 3 a); however, the amounts were low 
compared with that in the patients with plaque psor­
iasis. In the patients with GPP similar results were 
found; direct measurement showed free elastase activity
© 1997 British Association of Dermatologists, British Journal of Dermatohujii, I 37, .123-129
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Figure 4. Skin-derived antileueoproteinase levels in serial serum 
samples (À, left //-axis) and in our pustulation (#, right i/-axis) patient 
with IH. Day 0 is the day of admission* After delivery both the 
pustulation and the skin-derived antileueoproteinase level in serum 
decreased to normal values.
factors.16 However, others regard IH as a sepan 
entity because of its different clinical features and a
distinctive typical history. Our pi
with the characteristic clinical signs of IH. She had no 
history of skin disorders until her third pregnancy. In 
contrast with reports in the literature, her skin did not 
clear quickly after the delivery. Treatment with isotreti­
noin was starte
As IH presents during pregnancy, there is probably 
an aetiological relationship between 111 and 
nancy. After IH has once affected a pati 
presentation in each subsequent pregnancy has been
» ' i i»
] y - 2 ireported, 
induce IH in
Oral contracep ti ve
previously
to
in
pathological
mechanism has been determined so far. Hypocalcaemia 
is presumed to be of importance; it has been associt
in two of the three patients, whereas heat-inactivation 
liberated the anti-HLE activity. Anti-HLE values in IH 
and GPP were in the same range. In the patients with 
plaque psoriasis no free elastase activity was present, 
and total anti-HLE activity was high compared with 
that in patients with IH and GPP (Fig. 3b).
SKALP levels in scale extracts and in serum
In order to study the SKALP levels without possible 
interference by other elastase inhibitors, we used a
specific sandwich-type ELISA. SKALP levels, as 
measured with ELISA in the supernatant of boiled 
scale extracts, were higher than those obtained with 
the functional assay (Fig. 3b). This is probably due to the 
fact that in the ELISA both biologically active intact 
SKALP and degraded SKALP are measured. As with the 
functional assay, the SKALP concentration was signifi­
cantly lower in IH and in GPP compared with plaque
In the serial serum Sc 
measured SKALP
Serum
s of our patient with IH we 
using the ELISA technique.
of SKALP correlated with ■"“ a s e
activity shown by the formation of pustules (Fig. 4).
, followed
by a reduction of SKALP levels to normal values.
with IH.““ Patients with GPP and psoriasis vulgaris can 
experience reactivation of their disease during episodes
of hypocalcaemia. 17,2 3,24 One report of GPP patients
found hypocalcaemia in only live of 57 patients, and it 
was not found in subsequent equally severe periods of 
disease. The authors suggested that hypocalcaemia is a 
secondary phenomenon, due to a transient state of
1  F 7
malabsorption or low serum albumin. ' Whether hypo­
calcaemia is really a pathogenic factor in IH, as sug-
hypocalcaemia due to
i
gested in a patient
congenital rickets who developed Iii,2"’ or a
J  /  )  r
enon secondary to the loss of albumin,“ 
debatable. Another factor contributing to hypocalcae­
mia is the physiological decrease of total serum calcium 
level by 5-6% during pregnancy.“ In our patient the 
calcium level was in the normal range after correction 
for a low albumin level. The serum level of 25-hydroxy- 
vitamin D} was slightly decreased, with normal 1,25- 
dihydroxy vitamin D j and pan
In inflammatory skin diseases such as 
and in epidermal tumours'2 y SKALP is i 
epidermis forming a gradient of anti-elastase activity 
from epidermis to dermis. One of the putative functions 
of FILE is to facilitate migration of PMN through con­
nective tissue and basal membranes, towards inilam- 
matory foci. In our patient with IH we examined the 
amounts of SKALP in scales and serum during the
psoriasis(>,“‘s
in
Discussion
It is still a matter of debate whether IH should be 
considered as a separate entity or as a variant of GPP. 
Some authors consider both to be the result of a final
common pi ay by i ent pathogenic
it in g a
course of the disease. Most striking was the lack of 
free anti-HLE activity from 9 days after i 
these samples free HLE activity was found, i 
total saturation of all available anti-HLE ac 
heat inactivation, anti-HLE activity was found, due to 
the liberation of SKALP from its complex with HLE. 
However, the amount of total anti-HLE activity is lower
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by a factor of 5 than in plaque psoriasis. In the three 
patients with GPP we found similar results. We suggest 
that the local deficiency of SKALP as found in IH and 
GPP facilitates PMN migration into the epidermis, lead­
ing finally to a massive accumulation of PMN in the 
epidermis. It is not clear which mechanism leads to the 
decreased levels of SKALP. In keratotome biopsies of 
patients with plaque psoriasis and pustular psoriasis, no 
difference was seen in SKALP expression at the mRNA 
level.11 Whether the decrease of SKALP is caused by an 
enhanced inactivation and subsequent clearance needs 
to be studied in the future.
As SKALP is a cationic, low molecular weight protein, 
it can easily cross the basal membrane, penetrate the 
connective tissue and reach the circulation. SKALP can 
be demonstrated in the urine of psoriatic patients. 
Furthermore, we have reported a correlation of serum 
SKALP levels with disease activity in patients with
5 { A
psoriasis who were treated with cyclosporin A. In 
our patient serum levels of SKALP correlated well 
with the pustulation; however, the decrease of SKALP 
lags slightly behind the clearance of the pustules. 
Compared with patients with plaque psoriasis with a 
similar area of skin affected, the SKALP levels in IH are 
rather low (not shown).
In the patient with IH we have demonstrated a 
dynamic variation of SKALP in scales and serum 
during the course of the disease. In scales, anti-elastase 
activity dropped to undetectable levels, while free elas­
tase activity appeared. Serum levels of SKALP correlated 
with the disease activity. We suggest that in both GPP 
and IH a final common pathway is involved in the 
pathogenic mechanism of pustule formation. In both 
diseases a deficiency of SKALP could be of importance in 
pustule formation. These findings would imply that in 
both GPP and IH the use ol’ a low molecular weight drug 
with anti-elastase activity could be a new therapeutic 
modality.
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